It was a pleasure hosting visitors from AstraZeneca at our Hong Kong facilities last week: Prof. Ronald Li, CEO and Founder, and Dr. Bernard Fermini, Chief R&D Officer introduced to the guests our capabilities in revolutionizing #drugdiscovery using the MyHeart Platform.
The Japanese government has just approved the use of #iPS cells in clinical trials as treatment for spinal cord injuries, in addition to trials for heart failure and Parkinson’s, setting another precedent for global regenerative medicine development. https://t.co/O0olvL1I9Q
Alongside other industry leaders, our CEO Prof. Ronald Li shared at #Healthtech O2O Summit of @StartmeupHK Festival 2019 on how he had led @Novoheart to become a listed global technology company devoted to revolutionizing #DrugDiscovery. Read more on MIMS: https://t.co/gssIiEFqJf
Will tech change our bodies and health for the better? What will ageing look like in 2050? Come find out at our What'sNext - HealthTech event!
Register here: https://t.co/ef2UYhT0eO